2024
A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
Du Z, Wang L, Bai Y, Liu Y, Lau E, Galvani A, Krug R, Cowling B, Meyers L. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients. ELife 2024, 13: e89801. PMID: 38622989, PMCID: PMC11078542, DOI: 10.7554/elife.89801.Peer-Reviewed Original ResearchConceptsViral sheddingHospitalized COVID-19 patientsSARS-CoV-2Retrospective cohort studyRisk of reboundCOVID-19 patientsViral reboundTime of treatmentTreated patientsPreventing severe illnessEarly treatmentCohort studyHospitalized patientsPatientsViral replicationReducing infectiousnessSevere illnessTimely treatmentViral dynamicsHealth record dataTreatmentTransmission riskTransmission of SARS-CoV-2EfficacySymptoms
2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug use